InMode Acquires All The Intellectual Property Assets Of Viveve Medical; Terms Not Disclosed
All of Viveve's worldwide patents will be transferred and registered under InMode Ltd.Viveve is a medical technology company focused on women's wellness and the treatment of female stress urinary incontinence (SUI).
Viveve Medical (NASDAQ:VIVE) & Precision Optics (NASDAQ:POCI) Financial Comparison
Precision Optics (NASDAQ:POCI – Get Rating) and Viveve Medical (NASDAQ:VIVE – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses b
Viveve Medical (NASDAQ:VIVE) Cut to Neutral at Alliance Global Partners
Alliance Global Partners cut shares of Viveve Medical (NASDAQ:VIVE – Get Rating) from a buy rating to a neutral rating in a report published on Monday, The Fly reports. Viveve Medical Price Performan
Viveve Medical (NASDAQ:VIVE) Downgraded to "Neutral" at Alliance Global Partners
Alliance Global Partners lowered shares of Viveve Medical (NASDAQ:VIVE – Get Rating) from a buy rating to a neutral rating in a report issued on Monday morning, The Fly reports. Viveve Medical Price
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersOntrak (NASDAQ:OTRK) stock increased by 44.3% to $0.83 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.4 million. TC BioPharm (Holdings) (NASDAQ:TC
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersCelyad Oncology (NASDAQ:CYAD) stock moved upwards by 150.2% to $2.0 during Tuesday's regular session. Trading volume for Celyad Oncology's stock is 50.4 million as of 12:30 EST. This is 563061.
Stocks That Hit 52-Week Lows On Tuesday
 Tuesday saw 9 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Embecta (NASDAQ:EMBC) is the largest company in terms of market cap to set a new 52-week low this mo
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial
Viveve Medical Inc (NASDAQ:VIVE) announced topline results from the U.S. Pivotal PURSUIT clinical trial evaluating Viveve treatment for stress urinary incontinence (SUI) in women.The study did not mee
Viveve Crashes ~60% as Company Decides to Delist, Explore Sale After Trial Fails
Viveve Announces Topline Results From Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGL
Viveve Medical To Seek Strategic Alternatives And Will Be Delisted From Nasdaq; Company Announced Treatment For Female Stress Urinary Incontinence Did Not Meet Primary Endpoint
Viveve Medical, Inc. (NASDAQ:VIVE) today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to eva
Tivic Health Systems (NASDAQ:TIVC) Versus Viveve Medical (NASDAQ:VIVE) Critical Review
Tivic Health Systems (NASDAQ:TIVC – Get Rating) and Viveve Medical (NASDAQ:VIVE – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesse
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Expion360 Inc. (NASDAQ:XPON) shares jumped 175% to $2.70 after the company announced it has been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersExact Sciences (NASDAQ:EXAS) shares increased by 17.9% to $52.6 during Friday's pre-market session. The company's market cap stands at $9.3 billion. IMAC Holdings (NASDAQ:BACK) shares increased
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence With Final 12-month Follow-up Visits Concluded
Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urin
Short Interest in Viveve Medical, Inc. (NASDAQ:VIVE) Expands By 98.8%
Viveve Medical, Inc. (NASDAQ:VIVE – Get Rating) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 178,100 shares, an incr
Stocks That Hit 52-Week Lows On Monday
 Monday saw 196 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Brookfield Asset Mgmt (NYSE:BAM
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December
Stocks That Hit 52-Week Lows On Thursday
OnThursday, 137 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: PT Telkom Indonesia (NYSE:TLK) was the largest firm by market cap to set a new 52-week low.Palisade Bio
Viveve Medical (NASDAQ:VIVE) Shares Pass Below Fifty Day Moving Average of $0.64
Viveve Medical, Inc. (NASDAQ:VIVE – Get Rating) shares crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.64 and traded as low as
No Data